{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:59:29Z","timestamp":1761897569656,"version":"3.40.5"},"reference-count":28,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2021,7,9]],"date-time":"2021-07-09T00:00:00Z","timestamp":1625788800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>Determining values of plasma renin activity (PRA) or plasma active renin concentration (ARC), plasma aldosterone concentration (PAC), and aldosterone-to-renin ratio (ARR) is essential to diagnose primary aldosteronism (PA), but it takes several days with conventional radioimmunoassays (RIAs). Chemiluminescent enzyme immunoassays for PAC and ARC using the Accuraseed<jats:sup>\u00ae<\/jats:sup> immunoanalyzer facilitated the determination, but relations between Accuraseed<jats:sup>\u00ae<\/jats:sup> immunoanalyzer-based and RIA-based values in samples of PA confirmatory tests and adrenal venous sampling remained to be elucidated. We addressed this issue in the present study. This is a prospective, cross-sectional study. ARC and PAC values were measured by the Accuraseed<jats:sup>\u00ae<\/jats:sup> immunoanalyzer in samples, in which PRA and PAC values had been measured by the PRA-FR<jats:sup>\u00ae<\/jats:sup> RIA and SPAC<jats:sup>\u00ae<\/jats:sup>-S Aldosterone kits, respectively. The relations between Accuraseed<jats:sup>\u00ae<\/jats:sup> immunoanalyzer-based and RIA-based values were investigated with regression analyses. The optimal cutoff of Accuraseed<jats:sup>\u00ae<\/jats:sup> immunoanalyzer-based ARR for PA screening was determined by the receiver operating characteristic analysis. After log-log transformations, linear relations with high coefficients of determination were observed between Accuraseed<jats:sup>\u00ae<\/jats:sup> immunoanalyzer-based and RIA-based data of renin and aldosterone. Following the PA guidelines of Japan Endocrine Society, Accuraseed<jats:sup>\u00ae<\/jats:sup> immunoanalyzer-based cutoffs were calculated from the regression equations: the basal PAC for PA screening &gt;12 ng\/dL, PAC for the saline infusion test &gt;8.2 ng\/dL, ARC for the furosemide-upright test &lt;15 pg\/mL, and ARR for the captopril challenge test &gt;3.09 ng\/dL per pg\/mL. The optimal cutoff of Accuraseed<jats:sup>\u00ae<\/jats:sup> immunoanalyzer-based ARR for PA screening was &gt;2.43 ng\/dL over pg\/mL not to overlook bilateral PA patients. The present study provided conversion formulas between Accuraseed<jats:sup>\u00ae<\/jats:sup> immunoanalyzer-based and RIA-based values of renin, aldosterone, and ARR, not only in basal samples but also in samples of PA confirmatory tests and adrenal venous sampling. Although validation studies are awaited, the present study will become priming water of harmonization of renin and aldosterone immunoassays.<\/jats:p>","DOI":"10.1371\/journal.pone.0253807","type":"journal-article","created":{"date-parts":[[2021,7,9]],"date-time":"2021-07-09T17:54:30Z","timestamp":1625853270000},"page":"e0253807","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":6,"title":["Comparisons of plasma aldosterone and renin data between an automated chemiluminescent immunoanalyzer and conventional radioimmunoassays in the screening and diagnosis of primary aldosteronism"],"prefix":"10.1371","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4000-6215","authenticated-orcid":true,"given":"Naohisa","family":"Tamura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erika","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rumi","family":"Shirakawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4876-446X","authenticated-orcid":true,"given":"Eiji","family":"Nakatani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kanako","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Hatakeyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mizuki","family":"Torii-Hanakita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chika","family":"Kyo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rieko","family":"Kosugi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuo","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masato","family":"Kotani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Usui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuhide","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2021,7,9]]},"reference":[{"key":"pone.0253807.ref001","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1001\/archinternmed.2007.33","article-title":"Cardiovascular outcomes in patients with primary aldosteronism after treatment","volume":"168","author":"C Catena","year":"2008","journal-title":"Arch Intern Med"},{"key":"pone.0253807.ref002","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.jacc.2005.01.015","article-title":"Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism","volume":"45","author":"P Milliez","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"pone.0253807.ref003","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1161\/HYPERTENSIONAHA.117.10263","article-title":"Prevalence of Cardiovascular Disease and Its Risk Factors in Primary Aldosteronism: A Multicenter Study in Japan","volume":"71","author":"Y Ohno","year":"2018","journal-title":"Hypertension"},{"key":"pone.0253807.ref004","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1161\/HYPERTENSIONAHA.113.01060","article-title":"Cardiovascular complications associated with primary aldosteronism: a controlled cross-sectional study","volume":"62","author":"S Savard","year":"2013","journal-title":"Hypertension"},{"key":"pone.0253807.ref005","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1007\/BF03347840","article-title":"Vascular complications in patients with aldosterone producing adenoma in Japan: comparative study with essential hypertension","volume":"18","author":"R Takeda","year":"1995","journal-title":"J Endocrinol Investig"},{"key":"pone.0253807.ref006","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1291\/hypres.20.85","article-title":"Left ventricular hypertrophy is more prominent in patients with primary aldosteronism than in patients with other types of secondary hypertension","volume":"20","author":"A Tanabe","year":"1997","journal-title":"Hypertens Res"},{"key":"pone.0253807.ref007","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1681\/ASN.2004100878","article-title":"Relative Glomerular Hyperfiltration in Primary Aldosteronism","volume":"16","author":"J Ribstein","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"pone.0253807.ref008","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1210\/jc.2015-4061","article-title":"The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline","volume":"101","author":"JW Funder","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"pone.0253807.ref009","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1507\/endocrj.EJ11-0133","article-title":"Guidelines for the diagnosis and treatment of primary aldosteronism\u2014the Japan Endocrine Society 2009","volume":"58","author":"T Nishikawa","year":"2011","journal-title":"Endocr J"},{"key":"pone.0253807.ref010","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1038\/s41440-019-0284-9","article-title":"The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019)","volume":"42","author":"S Umemura","year":"2019","journal-title":"Hypertens Res"},{"key":"pone.0253807.ref011","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1038\/s41371-020-0336-2","article-title":"Primary aldosteronism is a public health issue: challenges and opportunities","volume":"34","author":"R Libianto","year":"2020","journal-title":"J Hum Hypertens"},{"key":"pone.0253807.ref012","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/jch.14173","article-title":"The effect of medication on the aldosterone-to-renin ratio. A critical review of the literature","volume":"23","author":"RM Alnazer","year":"2021","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"pone.0253807.ref013","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1507\/endocrj.EJ16-0304","article-title":"Calibration and evaluation of routine methods by serum certified reference material for aldosterone measurement in blood","volume":"63","author":"T Nishikawa","year":"2016","journal-title":"Endocr J"},{"key":"pone.0253807.ref014","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1210\/jc.2011-2384","article-title":"18-hydroxycorticosterone, 18-hydroxycortisol, and 18-oxocortisol in the diagnosis of primary aldosteronism and its subtypes","volume":"97","author":"P Mulatero","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"pone.0253807.ref015","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1161\/HYPERTENSIONAHA.117.09078","article-title":"Rapid Screening of Primary Aldosteronism by a Novel Chemiluminescent Immunoassay","volume":"70","author":"R Morimoto","year":"2017","journal-title":"Hypertension"},{"key":"pone.0253807.ref016","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1373\/clinchem.2008.116004","article-title":"Measurement of Aldosterone in Human Plasma by Semiautomated HPLC\u2013Tandem Mass Spectrometry","volume":"55","author":"PJ Taylor","year":"2009","journal-title":"Clin Chem"},{"volume-title":"The Japan Endocrine Society","year":"2020","author":"The Japan Endocrine Society","key":"pone.0253807.ref017"},{"key":"pone.0253807.ref018","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1515\/CCLM.2011.201","article-title":"Harmonization of growth hormone measurements with different immunoassays by data adjustment","volume":"49","author":"A Muller","year":"2011","journal-title":"Clin Chem Lab Med"},{"key":"pone.0253807.ref019","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1297\/cpe.15.79","article-title":"Standardization of blood growth hormone levels measured by different kits using a linear structural relationship","volume":"15","author":"T Saito","year":"2006","journal-title":"Clin Pediatr Endocrinol"},{"key":"pone.0253807.ref020","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1515\/cclm-2013-1038","article-title":"A statistical basis for harmonization of thyroid stimulating hormone immunoassays using a robust factor analysis model","volume":"52","author":"D Stockl","year":"2014","journal-title":"Clin Chem Lab Med"},{"key":"pone.0253807.ref021","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1210\/jc.2016-2935","article-title":"Harmonized Reference Ranges for Circulating Testosterone Levels in Men of Four Cohort Studies in the United States and Europe","volume":"102","author":"TG Travison","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"pone.0253807.ref022","article-title":"SPAC-S Aldosterone kit\u2014Measurements of aldosterone concentrations in blood and urine with a radioimmunoassay","volume-title":"Pharmaceuticals and Medical Devices Agency web site","author":"Fujirebio Inc","year":"2018","edition":"6"},{"key":"pone.0253807.ref023","volume-title":"Pharmaceuticals and Medical Devices Agency web site","author":"Fujirebio Inc","year":"2018","edition":"7"},{"key":"pone.0253807.ref024","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S0140-6736(65)91526-6","article-title":"A rapid test of adrenocortical function","volume":"285","author":"J Wood","year":"1965","journal-title":"The Lancet"},{"issue":"Suppl.Sep","key":"pone.0253807.ref025","first-page":"1","article-title":"Consensus statement on the clinical practice of primary aldosteronism in Japan","volume":"92","author":"The Japan Endocrine Society, the Japan Association of Endocrine Surgeons","year":"2016","journal-title":"Folia Endocrinologica Japonica"},{"key":"pone.0253807.ref026","first-page":"317","volume-title":"Model selection and multimodel inference: A practical information-theoretic approach","author":"KP Burnham","year":"2002","edition":"2"},{"key":"pone.0253807.ref027","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1093\/clinchem\/34.7.1379","article-title":"A review on the methodology for assessing diagnostic tests","volume":"34","author":"K Linnet","year":"1988","journal-title":"Clin Chem"},{"key":"pone.0253807.ref028","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1507\/endocrj.EJ19-0498","article-title":"Parameters of captopril challenge test can predict results of other confirmatory tests for primary aldosteronism and propose the next test to be done","volume":"67","author":"N Tamura","year":"2020","journal-title":"Endocr J"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0253807","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,5]],"date-time":"2021-08-05T02:31:31Z","timestamp":1628130691000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0253807"}},"subtitle":[],"editor":[{"given":"Michael","family":"Bader","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2021,7,9]]},"references-count":28,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2021,7,9]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0253807","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2021,7,9]]}}}